Studying a drug combination for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study is looking at how well a combination of medications works for people with advanced colorectal cancer that is microsatellite stable (MSS). The medications include chidamide, a PD-(L)1 inhibitor (a type of immunotherapy), and anti-angiogenic therapy (a treatment that blocks blood vessel growth to tumors).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced colorectal cancer that is called microsatellite stable (MSS) or proficient mismatch repair (pMMR).
- You can have had prior treatment with immunotherapy or anti-angiogenic drugs (like bevacizumab).
- Your doctor has determined that your general health level (ECOG score) is 0, 1, or 2.
- You have had at least one check-up after starting treatment to see how it worked.
- Your life expectancy is at least 3 months, and you have been on chidamide for more than 3 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
This study tests a combination of three drugs — Chidamide (a pill), an immunotherapy (PD-1/PD-L1 antibody), and anti-angiogenic agents (which block blood vessel growth to tumors) — for people with advanced colorectal cancer that has spread. The goal is to see how well they work together in real-world patients.
This trial tests a combination of four drugs (chidamide, a PD-1 inhibitor, bevacizumab, and XELOX chemotherapy) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if this combination can shrink tumors or slow the disease.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.